| Title |
Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders
|
|---|---|
| Published in |
CNS Drugs, August 2018
|
| DOI | 10.1007/s40263-018-0555-z |
| Pubmed ID | |
| Authors |
Michael J. Marmura, Aliza S. Kumpinsky |
| Abstract |
Anti-epileptic drugs are among the most effective drugs for migraine prophylaxis, and will likely continue to have a role even as new therapies emerge. Topiramate and valproate are effective for the preventive treatment of migraine, and other medications such as gabapentin or lamotrigine may have a role in the treatment of those with allodynia or frequent aura, respectively. Oxcarbazepine, carbamazepine, phenytoin, gabapentin, and others may alleviate pain in trigeminal neuralgia. While many anti-epileptic drugs can be effective in those with migraine or other headaches, most of these agents can potentially cause serious side effects. In particular, valproate, topiramate, carbamazepine, and phenytoin may lead to adverse outcomes for infants of exposed mothers. Valproate should not be given to women of childbearing potential for migraine prevention. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 59 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 12% |
| Student > Ph. D. Student | 4 | 7% |
| Student > Master | 4 | 7% |
| Student > Doctoral Student | 4 | 7% |
| Researcher | 3 | 5% |
| Other | 10 | 17% |
| Unknown | 27 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 29% |
| Neuroscience | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Agricultural and Biological Sciences | 1 | 2% |
| Unspecified | 1 | 2% |
| Other | 2 | 3% |
| Unknown | 32 | 54% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2018.
All research outputs
#15,542,250
of 23,098,660 outputs
Outputs from CNS Drugs
#1,100
of 1,318 outputs
Outputs of similar age
#210,118
of 331,122 outputs
Outputs of similar age from CNS Drugs
#20
of 26 outputs
Altmetric has tracked 23,098,660 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,318 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,122 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.